Sign in
CLYM Stock Price, Chart, Stats & News
Climb Bio, Inc.
Save
Climb Bio, Inc. (CLYM) does not currently pay a dividend.
656.81M
Market cap
–
Current P/E
–
Forward P/E
CLYM chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -35.68% |
ROE | -33.41% |
D/E | 0.00x |
Interest coverage ratio | – |
CLYM valuation
P/E | – |
P/S | – |
P/B | 2.95x |
P/CF | -8.70x |
P/FCF | -8.78x |
P/OCF | -8.70x |
PEG | 0.46x |
EV multiple | -8.06x |
About
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy.
Similar securities
Based on sector and market capitalization
Report issue